Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cambridge Global Asset Management was a Canadian investment management boutique within CI Investments that managed equity, income, balanced, dividend, and small-cap mandates for mutual funds and related investment products. It was not a biotechnology, pharmaceutical, or healthcare operating company, although some materials note selective investing exposure to healthcare and biotechnology as sectors within its portfolios. In November 2020, CI Investments announced that Cambridge Global Asset Management and several other legacy in-house boutiques would be phased out and operate under the CI Global Asset Management brand, with the rebrand scheduled for completion by the end of the first quarter of 2021. As a result, Cambridge Global Asset Management is best understood as a former brand/division rather than a currently active standalone company.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Cambridge Global Asset Management.